Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 38765 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

1This authority has been delegated from the 

Attorney General to the Administrator of the DEA 

by 28 CFR 0.100, and subsequently redelegated to 

the Deputy Assistant Administrator pursuant to 28 

CFR 0.104 and Section 7 of the appendix to subpart 

R of part 0. 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: July 16, 2021. 

Katherine Hiner, 

Acting Secretary to the Commission. 

[FR Doc. 2021–15553 Filed 7–21–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–372] 

Exempt Chemical Preparations Under 

the Controlled Substances Act 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Order with opportunity for 

comment. 

SUMMARY: The applications for exempt 

chemical preparations received by the 

Drug Enforcement Administration 

(DEA) between September 1, 2020, and 

March 31, 2021, as listed below, were 

accepted for filing and have been 

approved or denied as indicated. 

DATES: Interested persons may file 

written comments on this order in 

accordance with 21 CFR 1308.23(e). 

Electronic comments must be 

submitted, and written comments must 

be postmarked, on or before September 

20, 2021. Commenters should be aware 

that the electronic Federal Docket 

Management System will not accept 

comments after 11:59 p.m. Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–372’’ on all correspondence, 

including any attachments. 

Electronic comments: DEA encourages 

that all comments be submitted through 

the Federal eRulemaking Portal, which 

provides the ability to type short 

comments directly into the comment 

field on the web page or to attach a file 

for lengthier comments. Please go to 

http://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon completion 

of your submission you will receive a 

Comment Tracking Number for your 

comment. Please be aware that 

submitted comments are not 

instantaneously available for public 

view on Regulations.gov. If you have 

received a comment tracking number, 

your comment has been successfully 

submitted and there is no need to 

resubmit the same comment. 

Paper comments: Paper comments 

that duplicate the electronic submission 

are not necessary and are discouraged. 

Should you wish to mail a comment in 

lieu of an electronic comment, it should 

be sent via regular or express mail to: 

Drug Enforcement Administration, 

Attention: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

FOR FURTHER INFORMATION CONTACT: 

Terrence L. Boos, Ph.D., Diversion 

Control Division, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152; Telephone: (571) 362–8201. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received are considered part of the 

public record and made available for 

public inspection online at http://

www.regulations.gov and in the DEA’s 

public docket. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. The Freedom of 

Information Act applies to all comments 

received. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. 

Comments containing personal 

identifying information and confidential 

business information identified as 

directed above will generally be made 

publicly available in redacted form. If a 

comment has so much confidential 

business information that it cannot be 

effectively redacted, all or part of that 

comment may not be made publicly 

available. Comments posted to http://

www.regulations.gov may include any 

personal identifying information (such 

as name, address, and phone number) 

included in the text of your electronic 

submission that is not identified as 

directed above as confidential. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

Legal Authority 

Section 201 of the Controlled 

Substances Act (CSA) (21 U.S.C. 811) 

authorizes the Attorney General, by 

regulation, to exempt from certain 

provisions of the CSA certain 

compounds, mixtures, or preparations 

containing a controlled substance, if he 

finds that such compounds, mixtures, or 

preparations meet the requirements 

detailed in 21 U.S.C. 811(g)(3)(B).1 DEA 

regulations at 21 CFR 1308.23 and 

1308.24 further detail the criteria by 

which DEA’s Assistant Administrator 

may exempt a chemical preparation or 

mixture from certain provisions of the 

CSA. The Assistant Administrator may, 

pursuant to 21 CFR 1308.23(f), modify 

or revoke the criteria by which 

exemptions are granted and modify the 

scope of exemptions at any time. 

Exempt Chemical Preparation 

Applications Submitted Between 

September 1, 2020, and March 31, 2021 

The Assistant Administrator received 

applications between September 1, 

2020, and March 31, 2021, requesting 

exempt chemical preparation status 

detailed in 21 CFR 1308.23. Pursuant to 

the criteria stated in 21 U.S.C. 

811(g)(3)(B) and in 21 CFR 1308.23, the 

Assistant Administrator has found that 

each of the compounds, mixtures, and 

preparations described in Chart I below 

is intended for laboratory, industrial, 

educational, or special research 

purposes and not for general 

administration to a human being or 

animal and either: (1) Contains no 


lotter on DSK11XQN23PROD with NOTICES1
38766 Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 

narcotic controlled substance and is 

packaged in such a form or 

concentration that the packaged 

quantity does not present any 

significant potential for abuse; or (2) 

contains either a narcotic or nonnarcotic controlled substance and one or 

more adulterating or denaturing agents 

in such a manner, combination, 

quantity, proportion, or concentration 

that the preparation or mixture does not 

present any potential for abuse and, if 

the preparation or mixture contains a 

narcotic controlled substance, is 

formulated in such a manner that it 

incorporates methods of denaturing or 

other means so that the preparation or 

mixture is not liable to be abused or 

have ill effects, if abused, and so that 

the narcotic substance cannot in 

practice be removed. 

Accordingly, pursuant to 21 U.S.C. 

811(g)(3)(B), 21 CFR 1308.23, and 21 

CFR 1308.24, the Assistant 

Administrator has determined that each 

of the chemical preparations or mixtures 

generally described in Chart I below and 

specifically described in the application 

materials received by DEA is exempt, to 

the extent described in 21 CFR 1308.24, 

from application of sections 302, 303, 

305, 306, 307, 308, 309, 1002, 1003, and 

1004 (21 U.S.C. 822–823, 825–829, and 

952–954) of the CSA, and 21 CFR 

1301.74, as of the date that was 

provided in the approval letters to the 

individual requesters. 

Scope of Approval 

The exemptions are applicable only to 

the precise preparation or mixture 

described in the application submitted 

to DEA in the form(s) listed in this order 

and only for those above mentioned 

sections of the CSA and the CFR. In 

accordance with 21 CFR 1308.24(h), any 

change in the quantitative or qualitative 

composition of the preparation or 

mixture, or change in the trade name or 

other designation of the preparation or 

mixture after the date of application 

requires a new application. The 

requirements set forth in 21 CFR 

1308.24(b)–(e) apply to the exempted 

materials. In accordance with 21 CFR 

1308.24(g), DEA may prescribe 

requirements other than those set forth 

in 21 CFR 1308.24(b)–(e) on a case-bycase basis for materials exempted in 

bulk quantities. Accordingly, in order to 

limit opportunity for diversion from the 

larger bulk quantities, DEA has 

determined that each of the exempted 

bulk products listed in this order may 

only be used in-house by the 

manufacturer, and may not be 

distributed for any purpose, or 

transported to other facilities. 

Additional exempt chemical 

preparation requests received between 

September 1, 2020, and March 31, 2021, 

and not otherwise referenced in this 

order, may remain under consideration 

until DEA receives additional 

information required, pursuant to 21 

CFR 1308.23(d), as detailed in separate 

correspondence to individual 

requesters. DEA’s order on such 

requests will be communicated to the 

public in a future Federal Register 

publication. 

DEA also notes that these exemptions 

are limited to exemption from only 

those sections of the CSA and the CFR 

that are specifically identified in 21 CFR 

1308.24(a). All other requirements of the 

CSA and the CFR apply, including 

registration as an importer as required 

by 21 U.S.C. 957. 

CHART I 

Supplier Product name Form Application 

date 

Aalto Scientific, Ltd ............................ Cal Ver FLQ Drugs of Abuse for Roche Systems Level 1 ........................ Glass vial: 3 mL ............................... 2/23/2021 

Aalto Scientific, Ltd ............................ Cal Ver FLQ Drugs of Abuse for Roche Systems Level 2 ........................ Glass vial: 3 mL ............................... 2/23/2021 

Aalto Scientific, Ltd ............................ Cal Ver FLQ Drugs of Abuse for Roche Systems Level 3 ........................ Glass vial: 3 mL ............................... 2/23/2021 

Aalto Scientific, Ltd ............................ Linearity FD Fertility Siemens Centaur ...................................................... Kit: 10 vials; 3 mL each ................... 3/29/2021 

Aalto Scientific, Ltd ............................ Linearity FLQ TDM for Ortho Vitros ........................................................... Kit: 5 dropper bottles; 4 mL each .... 3/31/2021 

Agilent Technologies ......................... Custom Organic Std—11 analytes at 250 μg/mL ...................................... Amber ampule: 1 mL ....................... 2/19/2021 

Cambridge Isotope Laboratories, Inc Labeled Steroid Mix 40X Set S NSK-S-40X .............................................. Glass vial: 1 mL ............................... 3/1/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-tetrahydrocannabinol (THC) Unlabeled (95% CP), 1000 μg/mL in 

methanol (0.1%).

Glass ampule: 1.2 mL ...................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 100 μg/mL 

in methanol (0.01%).

Glass ampule: 1.2 mL ...................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Testosterone (2,3,4-13C3, 99%) 100 μg/mL in acetonitrile ....................... Glass ampule: 1 mL ......................... 2/19/2021 

Cayman Chemical Company ............ (+/¥)-11-hydroxy-d8-THC (CRM) 1 mg/ml, 1 mL in acetonitrile ............... Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ (+/¥)-11-hydroxy-d8-THC (CRM) 1 mg/ml, 1 mL in methanol ................. Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ (+/¥)-11-hydroxy-d8-THC (CRM) 100 μg/mL, 1 mL in acetonitrile ........... Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ (+/¥)-11-hydroxy-d8-THC (CRM) 100 μg/mL, 1 mL in methanol ............. Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Benzoylecgonine (CRM) 1 mg/mL, 1 mL in methanol ............................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Benzoylecgonine (CRM) 100 μg/mL, 1 mL in methanol ............................ Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Benzoylecgonine-d3 (CRM) 1 mg/mL, 1 mL in methanol .......................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Benzoylecgonine-d3 (CRM) 100 μg/mL, 1 mL in methanol ....................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Cocaine-d3 (CRM) 1 mg/mL, 1 mL in acetonitrile ..................................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Cocaine-d3 (CRM) 100 μg/mL, 1 mL in acetonitrile .................................. Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ D8-THCB (CRM) 100 μg/mL, 1 mL acetonitrile ......................................... Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCB (CRM) 1 mg/ml, 1 mL in acetonitrile ......................................... Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCB (CRM) 1 mg/ml, 1 mL methanol ................................................ Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCB (CRM) 100 μg/mL, 1 mL methanol ............................................ Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCP (CRM) 1 mg/ml, 1 mL in acetonitrile ......................................... Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCP (CRM) 1 mg/ml, 1 mL methanol ................................................ Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCP (CRM) 100 μg/mL, 1 mL acetonitrile ......................................... Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D8-THCP (CRM) 100 μg/mL, 1 mL methanol ............................................ Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ D9-THC Acetate (CRM) 1 mg/mL, 1 mL in acetonitrile ............................. Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ D9-THC Acetate (CRM) 1 mg/mL, 1 mL in methanol ................................ Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ D9-THC Acetate (CRM) 100 μg/mL, 1 mL in acetonitrile .......................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ D9-THC Acetate (CRM) 100 μg/mL, 1 mL in methanol ............................. Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Norfentanyl-d5 (CRM) 1 mg/mL, 1 mL in methanol ................................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Norfentanyl-d5 (CRM) 100 μg/mL, 1 mL in methanol ................................ Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 5 (CRM) 100 μg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 5 (CRM) 100 μg/mL 0.5 mL in acetonitrile.Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 38767 

CHART I—Continued 

Supplier Product name Form Application 

date 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 0.5 mL in acetonitrile Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 1 mL in 1:99 DIPEA: 

acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 1 mL in acetonitrile .. Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 100 μg/mL 1 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 100 μg/mL 1 mL in acetonitrile Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 250 μg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 250 μg/mL 0.5 mL in acetonitrile.Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 250 μg/mL 1 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 250 μg/mL 1 mL in acetonitrile Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 500 μg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 500 μg/mL 0.5 mL in acetonitrile.Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 500 μg/mL 1 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 6 (CRM) 500 μg/mL 1 mL in acetonitrile Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 1 mg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 1 mg/mL 0.5 mL in acetonitrile Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 1 mg/mL, 1 mL in 1:99 DIPEA: 

acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 1 mg/mL, 1 mL in acetonitrile Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 100 μg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 100 μg/mL 0.5 mL in acetonitrile.Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 100 μg/mL, 1 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 100 μg/mL, 1 mL in acetonitrile.Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 250 μg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 250 μg/mL 0.5 mL in acetonitrile.Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 250 μg/mL, 1 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 250 μg/mL, 1 mL in acetonitrile.Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 500 μg/mL, 1 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 500 μg/mL, 1 mL in acetonitrile.Glass ampule: 1 mL ......................... 2/3/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 500 μg/mL 0.5 mL in 1:99 

DIPEA: acetonitrile with 0.05% ascorbic acid.

Glass ampule: 0.5 mL ...................... 2/23/2021 

Cayman Chemical Company ............ Phytocannabinoid Acids Mixture 7 (CRM) 500 μg/mL 0.5 mL in acetonitrile.Glass ampule: 0.5 mL ...................... 2/3/2021 

Cayman Chemical Company ............ Psilocin (CRM) 1 mg/mL in Acetonitrile ..................................................... Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocin (CRM) 100 μg/mL in Acetonitrile .................................................. Glass ampule: 0.5 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocin-d10 (CRM) 1 mg/mL in Acetonitrile .............................................. Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocin-d10 (CRM) 100 μg/mL in Acetonitrile ........................................... Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocin-d4 (CRM) 1 mg/mL in Acetonitrile ................................................ Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocin-d4 (CRM) 100 μg/mL in Acetonitrile ............................................. Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocybin (CRM) 1 mg/mL in 1:1 Acetonitrile:H2O ................................... Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocybin (CRM) 100 μg/mL in 1:1 Acetonitrile:H2O ................................ Glass ampule: 0.5 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocybin-d10 (CRM) 1 mg/mL in 1:1 Acetonitrile:H2O ............................ Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocybin-d10 (CRM) 100 μg/mL in 1:1 Acetonitrile:H2O ......................... Glass ampule: 1.0 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocybin-d4 (CRM) 1 mg/mL in 1:1 Acetonitrile:H2O .............................. Glass ampule: 0.5 mL ...................... 2/24/2021 

Cayman Chemical Company ............ Psilocybin-d4 (CRM) 100 μg/mL in 1:1 Acetonitrile:H2O ........................... Glass ampule: 0.5 mL ...................... 2/24/2021 

Cayman Chemical Company ............ U-47700 (CRM) 1 mg/mL, 1 mL in methanol ............................................ Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ U-47700 (CRM) 100 μg/mL, 1 mL in methanol ......................................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ U-47700-d6 (CRM) 1 mg/mL, 1 mL in methanol ....................................... Glass ampule: 1 mL ......................... 2/23/2021 

Cayman Chemical Company ............ U-47700-d6 (CRM) 100 μg/mL, 1 mL in methanol .................................... Glass ampule: 1 mL ......................... 2/23/2021 

Cerilliant Corporation ......................... (¥)-delta8-THC-D3 .................................................................................... Glass ampule: 1 mL ......................... 1/26/2021 

Cerilliant Corporation ......................... 4-Methyl-alpha-pyrrolidinobutiophenone HCl (MPBP HCl) (1.0 mg/mL) ... Glass ampule: 1 mL ......................... 3/4/2021 

Cerilliant Corporation ......................... Tetrahydrocannabivarin-D5 (THCV-D5) ..................................................... Glass ampule: 1 mL ......................... 1/26/2021 

Cerilliant Corporation ......................... Tetrahydrocannabivarinic acid-D5 (THCVA-D5) ........................................ Glass ampule: 1 mL ......................... 1/26/2021 

Immunalysis Corporation ................... AMP/6-AM Oral Fluid Calibrator 1 ............................................................. Amber vial: 10 mL ............................ 2/10/2021 

Immunalysis Corporation ................... AMP/6-AM Oral Fluid Calibrator 2 ............................................................. Amber vial: 10 mL ............................ 2/10/2021 

Immunalysis Corporation ................... AMP/6-AM Oral Fluid Calibrator 3 ............................................................. Amber vial: 10 mL ............................ 2/10/2021 

Immunalysis Corporation ................... AMP/6-AM Oral Fluid Calibrator 4 ............................................................. Amber vial: 10 mL ............................ 2/10/2021 

Immunalysis Corporation ................... AMP/6-AM Oral Fluid Set ........................................................................... Kit: 2 vials, 10 mL each ................... 2/10/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 202 Kit 250 μg/mL in Acetonitrile .... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 203 Kit 500 μg/mL in Acetonitrile .... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 204 Kit 1000 μg/mL in Acetonitrile .. 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 205 Kit 250 μg/mL in Acetonitrile .... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 


lotter on DSK11XQN23PROD with NOTICES1
38768 Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 

CHART I—Continued 

Supplier Product name Form Application 

date 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 206 Kit 500 μg/mL in Acetonitrile .... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 207 Kit 1000 μg/mL in Acetonitrile .. 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 214 Kit 250 μg/mL in Acetonitrile .... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 214 Kit 250 μg/mL in Acetonitrile .... 1 Kit: 2 vials × 0.4 mL ...................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 215 Kit 500 μg/mL in Acetonitrile .... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 215 Kit 500 μg/mL in Acetonitrile .... 1 Kit: 2 vials × 0.4 mL ...................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 216 Kit 1000 μg/mL in Acetonitrile .. 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 216 Kit 1000 μg/mL in Acetonitrile .. 1 Kit: 2 vials × 0.4 mL ...................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 250 Kit 1000 μg/mL in Acetonitrile .. 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acid/Neutrals Mixture 250 Kit 1000 μg/mL in Acetonitrile .. 1 Kit: 2 vials × 0.4 mL ...................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 184 1000 μg/mL in Acetonitrile .................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 185 500 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 186 250 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 194 250 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 195 500 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 200 1000 μg/mL in Acetonitrile .................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 210 250 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 210 250 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 211 500 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 211 500 μg/mL in Acetonitrile ...................... Amber ampule: 0.4 mL .................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 212 1000 μg/mL in Acetonitrile .................... Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Acids Mixture 212 1000 μg/mL in Acetonitrile .................... Amber ampule: 0.4 mL .................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 187 100 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 188 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 189 1000 μg/mL in Acetonitrile .............................. Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 190 50 μg/mL in Acetonitrile .................................. Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 191 100 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 192 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 193 1000 μg/mL in Acetonitrile .............................. Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 197 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 198 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 213 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 254 250 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 254 250 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 255 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 255 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 10/9/2020 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 256 250 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 256 250 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/10/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 257 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 257 500 μg/mL in Acetonitrile ................................ Amber ampule: 0.4 mL .................... 3/10/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 258 Kit 250 μg/mL in Acetonitrile ........................... 1 kit: 2 vials × 0.4 mL ...................... 3/31/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 258 Kit 250 μg/mL in Acetonitrile ........................... 1 Kit: 2 vials × 0.4 mL ...................... 3/10/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 259 Kit 500 μg/mL in Acetonitrile ........................... 1 kit: 2 vials × 0.4 mL ...................... 3/19/2021 

LGC—Dr. Ehrenstorfer ...................... Cannabinoids Mixture 259 Kit 500 μg/mL in Acetonitrile ........................... 1 Kit: 2 vials × 0.4 mL ...................... 3/10/2021 

LGC—Dr. Ehrenstorfer ...................... Custom D9-Tetrahydrocannabivarin (THCV) 1000 ug/mL in Acetonitrile .. Amber ampule: 1 mL ....................... 1/19/2021 

LGC—Dr. Ehrenstorfer ...................... D9-Tetrahydrocannabivarinic acid (THCVA) 100 ug/mL in Acetonitrile ..... Amber ampule: 1 mL ....................... 3/10/2021 

o2si smart solutions .......................... Chloral Hydrate 1000 μg/mL in methanol .................................................. Amber ampule: 1 mL ....................... 3/24/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture CCV 16–0260, 10.0 μg/mL, 300 μL with 

a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture ICV (second source), 16–0260, 10.0 μg/ 

mL, 300 μL with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #1, 16–0260, 0.3 μg/mL, 300 μL 

with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #2, 16–0260, 1.0 μg/mL, 300 μL 

with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #3, 16–0260, 5.0 μg/mL, 300 μL 

with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #4, 16–0260, 10.0 μg/mL, 300 μL 

with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #5, 16–0260, 25.0 μg/mL, 300 μL 

with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #6, 16–0260, 50.0 μg/mL, 300 μL 

with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #7, 16–0260, 100.0 μg/mL, 300 

μL with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Level #8, 16–0260, 250.0 μg/mL, 300 

μL with a 2 mL silanized vial (ISO17034).

Amber ampule: 300 μL .................... 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Calibration Kit 16–0260, (2 × G34– 

140260–98).

1 kit; 26 amber ampules × 300 μL .. 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture Calibration Pack 16–0260, 13 × 1 ml .... 1 pack; 13 amber ampules × 300 μL 3/1/2021 

o2si smart solutions .......................... Custom Pharmaceutical Mixture LCS, 16–0260, 10.0 ug/mL, 1 mL with a 

2 ml Silanized Vial (ISO17034).

Amber ampule: 1 mL ....................... 3/1/2021 

Research Triangle Institute ............... 0584, 7232, 6089, 8785, 7227, 8588, 7541, 4336, 1817, 0737, 5340, 

2985, 8470, 3501, 7362, 6850, 5497, 4097, 2479, 1536, 7431, 9541, 

1585, 8534, 2113, 9789, 2482, 1013, 1483, 8092, 6365, 2209, 5434, 

4035, 9222, 9674, 5622, 3806, 1798, 9820.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 3370, 1411, 5883, 5713, 8800, 3630, 8683, 4541, 8161, 0359, 9704, 

2184, 0341, 2901, 0790, 6548, 3466, 0352, 5288, 8594, 0279, 8762, 

3687, 2819, 8743, 7197, 5064, 0199, 1609, 8643, 6467, 2245, 0706, 

0147, 6876, 3732, 9314, 1059, 8245, 8685.

HDPE tubes: 5 mL ........................... 3/11/2021 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 38769 

CHART I—Continued 

Supplier Product name Form Application 

date 

Research Triangle Institute ............... 4118, 3472, 9120, 3742, 9323, 4475, 5116, 7455, 3780, 9052, 4910, 

2630, 6141, 9351, 5220, 2730, 6408, 3560, 4063, 0427, 0669, 8350, 

9163, 6359, 0113, 1893, 4552, 2951, 1357, 8372, 9203, 3150, 9587, 

9290, 4399, 2454, 2468, 7560, 6645, 8756.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 4761, 2869, 4267, 9207, 1568, 8723, 7042, 6810, 0605, 7181, 8624, 

0015, 5050, 7046, 3626, 7515, 9023, 8821, 6767, 0861, 0689, 5934, 

2105, 2006, 1040, 5645, 2749, 7908, 9154, 8450, 5251, 6608, 3152, 

9027, 2731, 7530, 1329, 0320, 5833, 7580.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 4946, 2135, 7589, 456, 2617, 2224, 5066, 4134, 9514, 0206, 2691, 

2807, 1571, 2201, 0943, 6995, 1299, 3729, 9561, 2552, 1248, 7138, 

1634, 0813, 6352, 3567, 2017, 6701, 6915, 4448, 1967, 3179, 2480, 

5144, 8826, 5515, 0949, 6109, 4040, 8632.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 6673, 1920, 9080, 9040, 1769, 9824, 8015, 4813, 1535, 4285, 5824, 

7430, 3338, 2989, 2743, 1537, 6009, 4808, 0243, 7097, 5533, 6638, 

3414, 8238, 2573, 6806, 3959, 7896, 3448, 5652, 5273, 1341, 1063, 

6664, 9471, 7136, 3571, 8916, 8617, 8946.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 7155, 9763, 5721, 5161, 0009, 8118, 7420, 0527, 4415, 6892, 6896, 

8988, 6477, 9903, 6688, 0292, 9380, 4579, 9601, 7337, 1518, 2189, 

8886, 8880, 6963, 9446, 7721, 9988, 7688, 2525, 4017, 6826, 3426, 

4128, 6270, 4207, 0646, 5741, 6086, 0528.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 7938, 8287, 2990, 7693, 6858, 5995, 1929, 3740, 4461, 0196, 4271, 

9853, 5024, 6378, 3409, 2702, 7629, 6194, 4553, 2871, 0203, 4812, 

7073, 0834, 2732, 1841, 9545, 5063, 5062, 6234, 0210, 9740, 9472, 

9938, 5122, 8677, 3537, 5198, 5977, 8203.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 8497, 8384, 3406, 0324, 6930, 3165, 1564, 8858, 4968, 8840, 7836, 

9412, 9009, 0109, 0695, 0923, 0912, 3228, 6855, 5103, 8580, 4499, 

8347, 7831, 8420, 2875, 6778, 6680, 9098, 1987, 6813, 6572, 9943, 

6165, 0958, 5884, 1843, 2991, 3191, 1151.

HDPE tubes: 5 mL ........................... 3/11/2021 

Research Triangle Institute ............... 9493, 8564, 6768, 1670, 2733, 0560, 7822, 7495, 1290, 4534, 6583, 

3937, 6596, 2599, 9164, 5702, 8328, 9643, 5747, 1923, 0976, 3416, 

1445, 3834, 3069, 7609, 6580, 3945, 1726, 2891, 4325, 8970, 7248, 

1981, 3906, 0989, 3648, 7769, 4122, 9050.

HDPE tubes: 5 mL ........................... 3/11/2021 

Restek Corporation ........................... Cannabinoids Acids 7 Standard ................................................................. Glass ampule: 1.3 mL ...................... 3/31/2021 

UTAK Laboratories, Inc ..................... AED II MR Serum Control .......................................................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Amphetamines Panel Level 1 Urine Control .............................................. Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Amphetamines Panel Level 2 Urine Control .............................................. Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Benzodiazepines Hydrolysis QC Urine Control ......................................... Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Benzodiazepines Plus 100 ng/mL Urine Control ....................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Benzodiazepines Plus 100 ng/mL Whole Blood Control ........................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Benzodiazepines Plus 400 ng/mL Urine Control ....................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... DAU IA 1 Urine Control .............................................................................. Kit: 4 bottles, 10 mL each ................ 11/20/2020 

UTAK Laboratories, Inc ..................... DAU IA 2 Urine Control .............................................................................. Kit: 4 bottles, 10 mL each ................ 11/20/2020 

UTAK Laboratories, Inc ..................... DAU IA 3 Urine Control .............................................................................. Kit: 4 bottles, 10 mL each ................ 11/20/2020 

UTAK Laboratories, Inc ..................... DAU IA 4 Urine Control .............................................................................. Kit: 4 bottles, 10 mL each ................ 11/20/2020 

UTAK Laboratories, Inc ..................... DAU IA 5 Urine Control .............................................................................. Kit: 4 bottles, 10 mL each ................ 11/20/2020 

UTAK Laboratories, Inc ..................... DHEA Plus High Serum Control ................................................................ Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... DHEA Plus Low Serum Control ................................................................. Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Drugs of Abuse 200% Cutoff SMX Oral Fluid Control ............................... Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Drugs of Abuse 50% Cutoff SMX Oral Fluid Control ................................. Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Drugs of Abuse Cutoff SMX Oral Fluid Control ......................................... Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Drugs of Abuse Level 2 Whole Blood Control ........................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Miscellaneous Panel Level 1 Urine Control ............................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Miscellaneous Panel Level 2 Urine Control ............................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Opiates Hydrolysis QC Urine Control ........................................................ Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Pentobarbital Serum Control ...................................................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... STABBS Negative Serum Control .............................................................. Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... STABBS Positive Serum Control ............................................................... Kit: 5 bottles, 5 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Steroids Level 1 SMX Serum Control ........................................................ Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Steroids Level 2 SMX Serum Control ........................................................ Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Steroids Level 3 SMX Serum Control ........................................................ Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Steroids Level 4 SMX Serum Control ........................................................ Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Tapentadol Hydrolysis QC Urine Control ................................................... Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Urine Drug Screen Urine Control ............................................................... Kit: 5 bottles, 10 mL each ................ 11/20/2020 

UTAK Laboratories, Inc ..................... Z Drugs Plus Level 1 Urine Control ........................................................... Kit: 5 bottles, 3 mL each .................. 11/20/2020 

UTAK Laboratories, Inc ..................... Z Drugs Plus Level 2 Urine Control ........................................................... Kit: 5 bottles, 3 mL each .................. 11/20/2020 

Xvivo Perfusion ................................. Supplemented XVIVO Heart Solution (SXHS) ........................................... Glass vial: 10 mL ............................. 9/11/2020 

Xvivo Perfusion ................................. XVIVO Heart Perfusion System (XHPS) .................................................... Kit: Heart Box, Disposable, Supplemented Soln.9/11/2020 

The Assistant Administrator has 

found that each of the compounds, 

mixtures, and preparations described in 

Chart II below is not consistent with the 

criteria stated in 21 U.S.C. 811(g)(3)(B) 

and in 21 CFR 1308.23. Accordingly, the 

Assistant Administrator has determined 

that the chemical preparations or 

mixtures generally described in Chart II 

below and specifically described in the 

application materials received by DEA, 

are not exempt from application of any 

part of the CSA or from application of 

any part of the CFR, with regard to the 

requested exemption pursuant to 21 

CFR 1308.23, as of the date that was 

provided in the determination letters to 

the individual requesters. 


lotter on DSK11XQN23PROD with NOTICES1
38770 Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 

CHART II 

Supplier Product name Form Application 

date 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 5 

mg.

Glass ampule: 5 mg ......................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 

0.5 mg.

Glass ampule: 0.5 mg ...................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 1 

mg.

Glass ampule: 1 mg ......................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 

10 mg.

Glass ampule: 10 mg ....................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 5 mg ........ Glass ampule: 5 mg ......................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 0.5 mg ..... Glass ampule: 0.5 mg ...................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 1 mg ........ Glass ampule: 1 mg ......................... 2/19/2021 

Cambridge Isotopes Laboratories, 

Inc.

Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 10 mg ...... Glass ampule: 10 mg ....................... 2/19/2021 

Cayman Chemical Company ............ Clonazepam (CRM) 1 mg/mL, 1 mL in acetonitrile ................................... Glass ampule: 1 mL ......................... 2/23/2021 

LGC—Dr. Ehrenstorher ..................... D9-Tetrahydrocannabivarin 10,000 mg/L Parent stock in Methanol—NOT 

FOR SALE.

Boston Round, Amber glass: 14 mL 1/19/2021 

LGC—Dr. Ehrenstorfer ...................... Delta-9-THC 10000 μg/mL in Methanol ..................................................... Amber ampule: 2 mL ....................... 2/16/2021 

Opportunity for Comment 

Pursuant to 21 CFR 1308.23(e), any 

interested person may submit written 

comments on or objections to any 

chemical preparation in this order that 

has been approved or denied as exempt. 

If any comments or objections raise 

significant issues regarding any finding 

of fact or conclusion of law upon which 

this order is based, the Assistant 

Administrator will immediately 

suspend the effectiveness of any 

applicable part of this order until he 

may reconsider the application in light 

of the comments and objections filed. 

Thereafter, the Assistant Administrator 

shall reinstate, revoke, or amend his 

original order as he determines 

appropriate. 

Approved Exempt Chemical 

Preparations Are Posted on the DEA’s 

Website 

A list of all current exemptions, 

including those listed in this order, is 

available on the DEA’s website at http:// 

www.DEAdiversion.usdoj.gov/ 

schedules/exempt/exempt_chemlist.pdf. 

The dates of applications of all current 

exemptions are posted for easy 

reference. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–15024 Filed 7–21–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Parole Commission 

Sunshine Act Meeting 

Record of Vote of Meeting Closure 

(Public Law 94–409) (5 U.S.C. Sec. 

552b) 

I, Patricia K. Cushwa, Acting 

Chairman of the United States Parole 

Commission, was present at a meeting 

of said Commission, which started at 

approximately 2:30 p.m., on Tuesday, 

July 13, 2021, at the U.S. Parole 

Commission, 90 K Street NE, Third 

Floor, Washington, DC 20530. The 

purpose of the meeting was to discuss 

an original jurisdiction case pursuant to 

28 CFR 2.25. and 28 CFR 2.68(i)(1) Two 

Commissioners were present, 

constituting a quorum when the vote to 

close the meeting was submitted. 

Public announcement further 

describing the subject matter of the 

meeting and certifications of the General 

Counsel that this meeting may be closed 

by votes of the Commissioners present 

were submitted to the Commissioners 

prior to the conduct of any other 

business. Upon motion duly made, 

seconded, and carried, the following 

Commissioners voted that the meeting 

be closed: Patricia K. Cushwa and 

Charles T. Massarone. 

In witness whereof, I make this official 

record of the vote taken to close this 

meeting and authorize this record to be 

made available to the public. 

Patricia K. Cushwa, 

Acting Chairman, U.S. Parole Commission. 

[FR Doc. 2021–15788 Filed 7–20–21; 4:15 pm] 

BILLING CODE 4410–31–P 

SECURITIES AND EXCHANGE 

COMMISSION 

[Investment Company Act Release No. 

34333; 812–15219] 

Capital Southwest Corporation, et al.; 

Notice of Application 

July 16, 2021. 

AGENCY: Securities and Exchange 

Commission (‘‘Commission’’). 

ACTION: Notice. 

Notice of an application for an order 

under section 6(c) of the Investment 

Company Act of 1940 (the ‘‘Act’’) for an 

exemption from sections 18(a) and 61(a) 

of the Act. 

APPLICANTS: Capital Southwest 

Corporation (the ‘‘Company’’), Capital 

Southwest SBIC I, LP (the ‘‘Capital 

Southwest SBIC’’), and Capital 

Southwest SBIC I GP, LLC (the ‘‘SBIC 

GP’’). 

SUMMARY OF THE APPLICATION: The 

Company requests an order to permit it 

to adhere to a modified asset coverage 

requirement. 

FILING DATES: The application was filed 

on April 21, 2021, and amended on July 

14, 2021. 

HEARING OR NOTIFICATION OF HEARING: 

An order granting the requested relief 

will be issued unless the Commission 

orders a hearing. Interested persons may 

request a hearing by emailing the 

Commission’s Secretary at SecretarysOffice@sec.gov and serving applicants 

with a copy of the request by email. 

Hearing requests should be received by 

the Commission by 5:30 p.m. on August 

10, 2021, and should be accompanied 

by proof of service on applicants, in the 

form of an affidavit or, for lawyers, a 

certificate of service. Pursuant to rule 0– 


lotter on DSK11XQN23PROD with NOTICES1